arrow_back Back to App

Extending Drug Incentives for National Security Medical Countermeasures.

This Act extends the program that incentivizes pharmaceutical companies to develop drugs against chemical, biological, radiological, or nuclear threats until 2029. The goal is to ensure the US has necessary medical countermeasures to protect citizens and the military during a severe public health crisis or attack. It establishes a new list of priority drugs deemed critical for national security preparedness.
Key points
The Priority Review Voucher program, which speeds up drug approval, is extended for six years, until October 2029.
A new official list of drug categories essential for treating chemical, biological, or nuclear threats to public health and the Armed Forces must be established and maintained.
The changes aim to accelerate the availability of life-saving medicines needed during major national security emergencies.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_1122
Sponsor: Sen. Ernst, Joni [R-IA]
Process start date: 2023-03-30
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Prioritizing Medical Countermeasures for National Security Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_1122.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-03-30.

What are the main provisions?

Key points include:

  • The Priority Review Voucher program, which speeds up drug approval, is extended for six years, until October 2029.
  • A new official list of drug categories essential for treating chemical, biological, or nuclear threats to public health and the Armed Forces must be established and maintained.
  • The changes aim to accelerate the availability of life-saving medicines needed during major national security emergencies.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Ernst, Joni [R-IA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Security